Navigation Links
Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
Date:3/4/2009

ISELIN, N.J., March 4 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has completed a reevaluation of the size of the Phase 2b Dextofisopam trial for Irritable Bowel Syndrome IBS -D + A and has concluded that a smaller trial could achieve the objectives of the trial. As the Phase 2b trial is not going to be a registration /pivotal trial, the objectives that must be achieved in order to progress into a Phase 3 trial are to: (1) determine the best dose to move into Phase 3, (2) replicate the efficacy observed in the Phase 2a trial and, (3) determine the optimal endpoints for Phase 3. In addition, the Company's plan is to ensure that the Phase 2b package is attractive to a pharmaceutical company for further development.

The Company has determined that a 300 patient trial should be of sufficient size to achieve its objectives. Consequently, the current Dextofisopam trial targeting 480 patients will be reduced to 300 patients. This trial will continue to have four cohorts of female patients. Each cohort will have approximately 75 patients. There are three drug cohorts at 100 mg BID, 200mg BID, 300mg BID and placebo.

The trial currently has 295 patients randomized and enrollment will be closed when the 300 patient level is reached. The Company's decision to reduce the size of the current Phase 2b trial has been based on clinical and statistical input from the Company's expert consultants. An analysis of the trial sizes of other IBS drug candidates in Phase 2b trials indicated that, with approximately 75 patients per cohort, the Company would have sufficient numbers on which to make a decision on whether or not the drug can progress into Phase 3 testing.

As previously disclosed, the Company is seeking to raise the additional capital necessary to complete the Phase 2b trial. Assum
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
2. Pharmos Corporation Reports 2008 Third Quarter Results
3. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
4. Pharmos Restructures Operations in Israel
5. CVS Caremark Corporation Announces Quarterly Dividend
6. AMERIGROUP Corporation to Present at the Barclays Capital Global Healthcare Conference on March 10
7. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
8. Genaera Corporation Announces 2008 Financial Results
9. Baxa Corporation Acquires Florida-Based ForHealth Technologies™
10. Baxa Corporation Acquires Florida-Based ForHealth Technologies(TM)
11. Providence Service Corporation Announces That Avalon Correctional Services Has Abandoned Its Consent Solicitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... September as Brain Aneurysm Awareness Month , which was established by the ... , “Spreading awareness and education, and helping fund more research remains our top ...
(Date:9/2/2015)... ... September 02, 2015 , ... This Fall, as ... (BCAM), Bright Pink, a national non-profit focused on the prevention and early detection ... a campaign to educate women to be breast and ovarian self-aware and celebrate ...
(Date:9/1/2015)... CA (PRWEB) , ... September 01, 2015 , ... ... Business Times discusses the hundreds of thousands of plastic surgeries conducted each year ... and reality TV for the growing numbers. Beverly Hills-based plastic surgeon Payam Jarrah-Nejad, ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Capillus82™ ... treatment of androgenic alopecia in adults, announces Miami-based medical device manufacturer, Capillus, LLC. ... also demonstrating its safety when used at home to combat hair loss. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ProRehab Physical Therapy , ... partnership with Apex Physical Therapy (Apex) is official as of August ... compassionate, and empathetic care to local residents from their combined eight locations throughout ...
Breaking Medicine News(10 mins):Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3
... Safety Project Report Makes Recommendations for System in Critical Need ... Nov. 17 Weaknesses in food safety policy, organization and ... Saintpaul, according to a report released today by the Produce ... at Georgetown University . , ...
... MYL ) today announced that its subsidiary, Mylan ... Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) ... , Fluoxetine Capsules, indicated for ... version of Eli Lilly,s Sarafem(R) Pulvules(R) Capsules. This product had ...
... procedure in which her stem cells were combined with ... , , TUESDAY, Nov. 18 (HealthDay News) -- In a ... undergone the first transplantation of a breathing passage fashioned ... researchers report. , As of now, the woman, Claudia ...
... as Chairman, Tony Strange Appointed to CEO position and Will ... , MELVILLE, N.Y., Nov. 18 /PRNewswire-FirstCall/ ... ), a leading provider of comprehensive home health services, announced ... succession plan. Effective January 1, 2009, Tony Strange will ...
... and Policy Center (NLPC), a plaintiff in the successful 1993 ... Clinton,s health care task force, today criticized Barack Obama for ... , According to NLPC President Peter ... General. His track record is not one of independence or ...
... mechanisms, scientists show , , TUESDAY, Nov. 18 (HealthDay News) ... mechanisms, according to a Washington University study that challenges ... version of the body,s response to pain. , This ... itching and pain. , Zhou-Feng Chen, of Washington University,s ...
Cached Medicine News:Health News:Salmonella Saintpaul Outbreak Exposes Food Safety Weaknesses 2Health News:Salmonella Saintpaul Outbreak Exposes Food Safety Weaknesses 3Health News:Airway Transplant Aided by Stem Cells a Medical First 2Health News:Airway Transplant Aided by Stem Cells a Medical First 3Health News:Gentiva Health Services Confirms Management Succession 2Health News:Gentiva Health Services Confirms Management Succession 3Health News:Gentiva Health Services Confirms Management Succession 4Health News:NLPC Criticizes Obama's Choice of Eric Holder for Attorney General Because of Role in Health Care Task Force Cover-Up 2Health News:Itching Not a Less Intense Form of Pain 2
(Date:9/1/2015)... , Sept. 1, 2015 Nevro Corp. (NYSE: ... is providing innovative evidence-based solutions for the treatment of ... its preliminary response to the Patent Trial and Appeals ... inter partes review (IPR), filed by a unit of ... in U.S. Patent No. 8,359,102 (the ,102 patent). The ,102 ...
(Date:9/1/2015)... and BRUSSELS , ... ) and UCB (Euronext Brussels: UCB) today announced ... effect of RomosozUmab Compared with Teriparatide in postmenopaUsal ... pReviously treated with bisphosphonatE therapy). The study (NCT01796301) ... difference in favor of romosozumab in the percent ...
(Date:9/1/2015)... N.J. , Sept. 1, 2015 Konica ... CS-7s Computed Radiography (CR) system, designed to deliver enterprise ... By utilizing the same Control Station as the Konica ... assured with an upgrade path from CR to DR. ... imaging to help improve workflow with unparalleled reliability and ...
Breaking Medicine Technology:Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2
... ALLENTOWN, Pa., May 8, 2012 Brainybrawn, Inc. ... that its subsidiary Sanvi Infotech Pvt. Ltd (India) has ... MCIMS ), a web based application for comprehensive information ... announced that its subsidiary Sanvi Infotech Pvt. Ltd (India) ...
... 8, 2012  eCardio Diagnostics, President and Chief Executive Officer, ... upcoming event presented by Comcast Business Class and Inc. ... event series, "Act at the Speed of Opportunity," is ... and provides attendees with information that can be used ...
Cached Medicine Technology:Brainybrawn, Inc. announces Launch of its Web based Medical College Information Management Solution (Sanvi MCIMS), as well as Receipt of Order for Its Comprehensive Restaurant Information Management Solution for Managing Chain of Restaurants (Sanvi 2Brainybrawn, Inc. announces Launch of its Web based Medical College Information Management Solution (Sanvi MCIMS), as well as Receipt of Order for Its Comprehensive Restaurant Information Management Solution for Managing Chain of Restaurants (Sanvi 3eCardio's CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc. 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: